<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5707">
  <stage>Registered</stage>
  <submitdate>18/11/2014</submitdate>
  <approvaldate>18/11/2014</approvaldate>
  <nctid>NCT02296853</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics of Tenofovir Alafenamide in Adults With Normal Hepatic Function and Severe Hepatic Impairment</studytitle>
    <scientifictitle>A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-004426-18</secondaryid>
    <secondaryid>GS-US-320-1615</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B Virus</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TAF

Experimental: TAF - Severe Hepatic Impairment - Participants with severe hepatic impairment will receive a single dose of TAF.

Active Comparator: TAF - Normal Hepatic Function - Participants with normal hepatic function will receive a single dose of TAF.


Treatment: drugs: TAF
Tenofovir alafenamide (TAF) 25 mg tablet administered orally

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma pharmacokinetics (PK) profiles of TAF and TFV: AUClast, AUCinf, and Cmax - This composite endpoint will measure the plasma PK profiles of TAF and TFV. PK parameters that will be measured include AUClast, AUCinf, and Cmax.</outcome>
      <timepoint>Predose and postdose on Day 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidences of adverse events and graded laboratory abnormalities</outcome>
      <timepoint>Up to 31 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Screening labs within defined thresholds

          -  Creatinine clearance must be = 60 mL/min</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Females who are pregnant or nursing or males who have a pregnant partner

          -  Infection with hepatitis B virus (HBV) or HIV

          -  History of clinically significant illness (including psychiatric or cardiac) or any
             other medical disorder that may interfere with participant treatment and/or adherence
             to the protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and
      it's metabolite tenofovir (TFV) along with the safety and tolerability of TAF in participants
      with normal hepatic function and severe hepatic impairment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02296853</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John F Flaherty, Pharm. D.</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>